News | June 09, 2026
Mariska Hargitay launches Bristol Myers Squibb's Myeloma Awareness Campaign
The campaign places renewed focus on a disease that remains incurable despite major scientific advances
The campaign places renewed focus on a disease that remains incurable despite major scientific advances
The approval is supported by results from the Phase 3 SWOG 1826 trial
These approvals represent a defining moment for people living with classical Hodgkin Lymphoma
The FDA aims to make a decision by April 8, 2026
This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia
The refocused commercial set-up will increase organizational efficiency and alignment across all commercial functions globally
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
